09:54 AM EST - Aeterna Zentaris Inc. : Announced that Ghryvelin™ (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults (AGHD), is now available to healthcare professionals across Europe (subject to reimbursement). This availability is possible thanks to Aeterna’s licensing partner, Consilient Health, Ltd., a privately-owned pharmaceutical company focused on commercializing medicines in Europe and Middle East. Aeterna Zentaris Inc.
shares T.AEZS are trading unchanged at $0.26.
